ConforMIS, Inc. (NASDAQ:CFMS) CTO Daniel Steines sold 15,485 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $3.15, for a total transaction of $48,777.75. Following the transaction, the chief technology officer now directly owns 254,652 shares of the company’s stock, valued at $802,153.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Daniel Steines also recently made the following trade(s):
- On Wednesday, October 18th, Daniel Steines sold 907 shares of ConforMIS stock. The stock was sold at an average price of $3.51, for a total transaction of $3,183.57.
Shares of ConforMIS, Inc. (NASDAQ:CFMS) traded up $0.06 during trading on Friday, hitting $3.27. 387,530 shares of the company were exchanged, compared to its average volume of 196,654. The company has a quick ratio of 5.38, a current ratio of 6.19 and a debt-to-equity ratio of 0.52. ConforMIS, Inc. has a 1-year low of $3.03 and a 1-year high of $9.59.
ConforMIS (NASDAQ:CFMS) last announced its earnings results on Wednesday, November 1st. The medical instruments supplier reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. The business had revenue of $18.40 million during the quarter, compared to analysts’ expectations of $17.55 million. ConforMIS had a negative net margin of 72.70% and a negative return on equity of 76.88%. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.31) EPS. equities research analysts forecast that ConforMIS, Inc. will post -1.27 EPS for the current fiscal year.
A number of equities analysts have recently commented on CFMS shares. Oppenheimer Holdings, Inc. set a $6.00 price objective on shares of ConforMIS and gave the stock a “buy” rating in a report on Friday, August 4th. BTIG Research reaffirmed a “hold” rating on shares of ConforMIS in a report on Thursday, November 2nd. Zacks Investment Research downgraded shares of ConforMIS from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Deutsche Bank AG reiterated a “hold” rating and set a $5.00 target price (down previously from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. Finally, ValuEngine upgraded shares of ConforMIS from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. ConforMIS currently has an average rating of “Hold” and an average target price of $5.85.
Several institutional investors have recently made changes to their positions in CFMS. Granite Investment Partners LLC acquired a new stake in shares of ConforMIS during the 3rd quarter worth about $859,000. Goldman Sachs Group Inc. increased its position in shares of ConforMIS by 1,313.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 148,147 shares of the medical instruments supplier’s stock worth $773,000 after purchasing an additional 137,667 shares in the last quarter. Ark Investment Management LLC increased its position in shares of ConforMIS by 208.5% during the 2nd quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock worth $825,000 after purchasing an additional 130,009 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of ConforMIS during the 2nd quarter worth about $430,000. Finally, Citadel Advisors LLC increased its position in ConforMIS by 331.2% in the 3rd quarter. Citadel Advisors LLC now owns 113,972 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 87,540 shares in the last quarter. Institutional investors and hedge funds own 32.83% of the company’s stock.
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.